Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMMVB5P)

Drug Name
BOLDINE Drug Info
Synonyms
Boldine; 476-70-0; Uniboldina; Boldin; (S)-Boldine; Boldine chloroform; (+)-Boldine; NSC 65689; UNII-8I91GE2769; (S)-(+)-Boldine; EINECS 207-509-9; BRN 0094036; 1,10-Dimethoxy-2,9-dihydroxyaporphine; CHEMBL388342; CHEBI:3148; 1,10-Dimethoxy-6a-alpha-aporphine-2,9-diol; LZJRNLRASBVRRX-ZDUSSCGKSA-N; 8I91GE2769; 4H-Dibenzo(de,g)quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (S)-; 4H-Dibenzo(de,g)quinoline-2,9-diol, 5,6,6a,7-tetrahydro-1,10-dimethoxy-6-methyl-, (6aS)-
Cross-matching ID
PubChem CID
10154
ChEBI ID
CHEMBL388342
CAS Number
CAS 476-70-0
TTD Drug ID
D0LH4L

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Staphylococcus aureus infection 2.38 0.00e+0 72/95 (75.79%) C1S;DEFA4;CFD;...
Retinol metabolism 1.99 0.00e+0 41/68 (60.29%) ADH1B;HSD17B6;ALDH1A3;...
Systemic lupus erythematosus 1.93 5.36e-3 45/135 (33.33%) C1S;HLA-DPB1;ELANE;...
RNA polymerase 1.83 1.00e-2 23/31 (74.19%) POLR2I;POLR1D;POLR3K;...
DNA replication 1.81 8.04e-3 34/36 (94.44%) RFC3;RPA3;SSBP1;...
Pentose and glucuronate interconversions 1.78 1.61e-2 17/34 (50%) SORD;UGP2;UGT2B28;...
Viral protein interaction with cytokine and cytokine re... 1.78 1.49e-2 84/100 (84%) CCL19;CXCL12;CCL21;...
Drug metabolism 1.77 1.61e-2 78/151 (51.66%) ALDH3A1;GSTP1;NME3;...
Renin-angiotensin system 1.73 2.32e-2 20/23 (86.96%) KLK2;CPA3;AGTR1;...
PPAR signaling pathway 1.72 2.25e-2 66/74 (89.19%) FABP5;FABP4;PPARG;...
FoxO signaling pathway -1.58 4.70e-2 118/131 (90.08%) MAPK14;CREBBP;HOMER3;...
Inflammatory mediator regulation of TRP channels -1.59 4.73e-2 82/98 (83.67%) CAMK2G;MAPK14;PLCB4;...
Legionellosis -1.60 4.69e-2 51/57 (89.47%) HSPA8;NAIP;CASP9;...
Salivary secretion -1.60 4.72e-2 76/93 (81.72%) ATP2B1;AQP5;GUCY1A2;...
Apoptosis -1.61 4.61e-2 126/168 (75%) NRAS;BCL2L11;PMAIP1;...
Oxytocin signaling pathway -1.61 4.72e-2 128/154 (83.12%) PRKAB2;ROCK1;CAMK2G;...
Chronic myeloid leukemia -1.61 4.55e-2 72/76 (94.74%) CRK;PIK3CA;TGFBR1;...
Parathyroid hormone synthesis, secretion and action -1.62 4.59e-2 98/106 (92.45%) FGFR1;PLCB4;CREB1;...
Notch signaling pathway -1.63 4.66e-2 49/59 (83.05%) EP300;JAG2;DLL3;...
Thyroid hormone synthesis -1.63 4.56e-2 66/75 (88%) PLCB4;TTF1;CREB1;...
Vasopressin-regulated water reabsorption -1.67 4.50e-2 40/44 (90.91%) ARHGDIB;DCTN1;DYNC1I1;...
Cortisol synthesis and secretion -1.68 4.61e-2 58/65 (89.23%) CACNA1H;PLCB4;CREB1;...
Phosphatidylinositol signaling system -1.70 3.80e-2 82/97 (84.54%) DGKA;IMPA2;SYNJ2;...
Human papillomavirus infection -1.70 3.95e-2 284/331 (85.8%) CREBBP;UBE3A;LAMA3;...
mTOR signaling pathway -1.71 3.82e-2 114/154 (74.03%) MAP2K1;RRAGD;PTEN;...
African trypanosomiasis -1.72 3.76e-2 32/37 (86.49%) HBB;SELE;APOL1;...
Thyroid hormone signaling pathway -1.74 3.00e-2 112/121 (92.56%) NRAS;CASP9;AKT3;...
Longevity regulating pathway -1.76 3.05e-2 90/151 (59.6%) IRS1;PRKAB2;RPS6KB2;...
Ovarian steroidogenesis -1.77 3.20e-2 41/51 (80.39%) LHB;ADCY3;BMP6;...
Measles -1.77 3.27e-2 133/139 (95.68%) PIK3CA;OAS3;MAPK10;...
Bladder cancer -1.78 3.24e-2 40/41 (97.56%) CDKN2A;HBEGF;CDKN1A;...
Antigen processing and presentation -1.78 3.60e-2 60/78 (76.92%) CREB1;NFYA;TAP2;...
Various types of N-glycan biosynthesis -1.81 2.70e-2 26/39 (66.67%) ALG3;STT3A;B4GALT3;...
GnRH signaling pathway -1.88 1.37e-2 80/93 (86.02%) CAMK2G;MAPK14;PLCB4;...
Estrogen signaling pathway -1.90 1.60e-2 119/137 (86.86%) PLCB4;CREB1;GNAQ;...
Nicotinate and nicotinamide metabolism -1.92 1.44e-2 25/35 (71.43%) SIRT2;NMNAT2;NNMT;...
Autophagy -2.03 3.00e-3 113/169 (66.86%) TBK1;HIF1A;PIK3R4;...
Lysosome -2.04 0.00e+0 115/128 (89.84%) GLA;HEXA;ATP6V0D1;...
Protein processing in endoplasmic reticulum -2.24 0.00e+0 127/171 (74.27%) SEC24C;SEC61A1;NPLOC4;...
Mitophagy -2.31 0.00e+0 56/68 (82.35%) MITF;RAB7A;MAPK10;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 6.66uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H